PriceTargets.com logo

AlloVir - ALVR Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.45 As of 01/8/2025 05:00 PM ET
▼ -0.0267 (-5.60%)

This chart shows the closing price for ALVR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AlloVir Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALVR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALVR

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for AlloVir in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.45.

This chart shows the closing price for ALVR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in AlloVir. This rating changed within the last month from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/18/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/16/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
1/14/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
4/13/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
7/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
10/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/26/2023Bank of AmericaDowngradeBuy ➝ Underperform
12/22/2023Leerink PartnrsDowngradeOutperform ➝ Market Perform
12/22/2023Leerink PartnersDowngradeOutperform ➝ Market Perform
12/22/2023Piper SandlerDowngradeOverweight ➝ Neutral
12/22/2023JPMorgan Chase & Co.DowngradeOverweight ➝ Underweight
8/18/2023Bank of AmericaInitiated CoverageBuy$17.00
8/7/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$20.00
4/26/2023SVB SecuritiesBoost Target$16.00 ➝ $19.00
1/27/2023Morgan StanleyLower TargetOverweight$27.00 ➝ $20.00
1/23/2023Leerink PartnersLower TargetOutperform$25.00 ➝ $19.00
11/7/2022Leerink PartnersBoost TargetOutperform$24.00 ➝ $25.00
9/9/2022Morgan StanleyLower TargetOverweight$32.00 ➝ $27.00
7/28/2022Leerink PartnersLower TargetOutperform$30.00 ➝ $23.00
5/18/2022Piper SandlerLower TargetOverweight$55.00 ➝ $34.00
2/10/2022Leerink PartnersLower TargetOutperform$32.00 ➝ $30.00
2/1/2022BMO Capital MarketsInitiated CoverageOutperform$130.00
1/18/2022Morgan StanleyLower TargetOverweight$48.00 ➝ $45.00
12/17/2021Leerink PartnersLower TargetOutperform$37.00 ➝ $32.00
11/8/2021Leerink PartnersLower TargetOutperform$41.00 ➝ $37.00
10/12/2021Morgan StanleyBoost TargetOverweight$47.00 ➝ $48.00
9/29/2021Morgan StanleyBoost TargetOverweight$175.00 ➝ $225.00
8/22/2021Leerink PartnersInitiated CoverageBuy
8/18/2021Morgan StanleyLower TargetOverweight$50.00 ➝ $47.00
5/6/2021Leerink PartnersBoost TargetOutperform$41.00 ➝ $42.00
4/19/2021Morgan StanleyBoost TargetOverweight$49.00 ➝ $50.00
2/11/2021Piper SandlerBoost Target$52.00 ➝ $55.00
8/24/2020Piper SandlerInitiated CoverageOverweight
8/24/2020JPMorgan Chase & Co.Initiated CoverageOverweight$50.00
8/24/2020Leerink PartnersInitiated CoverageOutperform$41.00
8/24/2020Morgan StanleyInitiated CoverageOverweight$49.00
(Data available from 1/9/2020 forward)

News Sentiment Rating

0.98 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/13/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/13/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/12/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/11/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/11/2024
  • 1 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/10/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/10/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/9/2025

Current Sentiment

  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

AlloVir logo
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $0.45
Low: $0.44
High: $0.51

50 Day Range

MA: $0.56
Low: $0.40
High: $1.01

52 Week Range

Now: $0.45
Low: $0.40
High: $1.05

Volume

197,711 shs

Average Volume

262,802 shs

Market Capitalization

$51.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65

Frequently Asked Questions

What sell-side analysts currently cover shares of AlloVir?

The following Wall Street analysts have issued stock ratings on AlloVir in the last year:
View the latest analyst ratings for ALVR.

What is the current price target for AlloVir?

0 Wall Street analysts have set twelve-month price targets for AlloVir in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for AlloVir in the next year.
View the latest price targets for ALVR.

What is the current consensus analyst rating for AlloVir?

AlloVir currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ALVR.

What other companies compete with AlloVir?

Other companies that are similar to AlloVir include Sagimet Biosciences, LifeVantage, Cybin, Alector and Lyell Immunopharma. Learn More about companies similar to AlloVir.

How do I contact AlloVir's investor relations team?

AlloVir's physical mailing address is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. The company's listed phone number is 617-433-2605 and its investor relations email address is [email protected]. The official website for AlloVir is www.allovir.com. Learn More about contacing AlloVir investor relations.